Incyte's Strong Opzelura Sales Offset by Regulatory Uncertainty, RBC Says

MT Newswires Live10-31 00:14

Incyte's (INCY) Q3 performance was supported by strong Opzelura sales, but regulatory uncertainty remains a key challenge, RBC Capital Markets said in a note Thursday.

The analysts said Opzelura generated $255 million in sales, beating the $232 million estimate due to increased new patient starts. Smaller products, including Niktimvo and Zynyz, also performed well, while Jakafi sales were in line at $827 million.

Operating expenses were as expected, and the company's increased full-year net sales guidance of $5.21 billion to $5.30 billion is expected to be "easily achievable," the analysts added.

Looking ahead, Incyte has a growing solid tumor pipeline and positive prospects for its first-line myelofibrosis data and next-generation mCALR program. However, regulatory uncertainty around mCALR and less certain opportunities in immunology and inflammation remain risks, the analysts said.

RBC raised its price target on Incyte to $117 from $114 while keeping its sector perform rating.

Price: 120.24, Change: +3.44, Percent Change: +2.94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment